These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 35292989)

  • 1. Efficacy and safety of favipiravir plus interferon-beta versus lopinavir/ritonavir plus interferon-beta in moderately ill patients with COVID-19: A randomized clinical trial.
    Hassaniazad M; Farshidi H; Gharibzadeh A; Bazram A; Khalili E; Noormandi A; Fathalipour M
    J Med Virol; 2022 Jul; 94(7):3184-3191. PubMed ID: 35292989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The comparison of favipiravir and lopinavir/ritonavir combination in COVID-19 treatment.
    Çınarka H; Günlüoğlu G; Çörtük M; Yurt S; Kıyık M; Koşar F; Tanrıverdi E; Arslan MA; Baydili KN; Koç AS; Altın S; Çetinkaya E
    Turk J Med Sci; 2021 Aug; 51(4):1624-1630. PubMed ID: 33726482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial.
    Hassaniazad M; Bazram A; Hassanipour S; Fathalipour M
    Trials; 2020 Oct; 21(1):886. PubMed ID: 33109246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Observational study of the effects of Favipiravir vs Lopinavir/Ritonavir on clinical outcomes in critically Ill patients with COVID-19.
    Kocayiğit H; Özmen Süner K; Tomak Y; Demir G; Yaylacı S; Dheir H; Güçlü E; Erdem AF
    J Clin Pharm Ther; 2021 Apr; 46(2):454-459. PubMed ID: 33128482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydroxychloroquine versus lopinavir/ritonavir in severe COVID-19 patients : Results from a real-life patient cohort.
    Karolyi M; Pawelka E; Mader T; Omid S; Kelani H; Ely S; Jilma B; Baumgartner S; Laferl H; Ott C; Traugott M; Turner M; Seitz T; Wenisch C; Zoufaly A
    Wien Klin Wochenschr; 2021 Apr; 133(7-8):284-291. PubMed ID: 32776298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the Efficacy and Safety of Atazanavir/Ritonavir Plus Hydroxychloroquine with Lopinavir/Ritonavir Plus Hydroxychloroquine in Patients with Moderate COVID-19, A Randomized, Double-blind Clinical Trial.
    Nekoukar Z; Ala S; Moradi S; Hill A; Davoudi Badabi AR; Alikhani A; Alian S; Moghimi M; Shabani AM; Abbaspour Kasgari H
    Iran J Pharm Res; 2021; 20(4):278-288. PubMed ID: 35194446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.
    Irvani SSN; Golmohammadi M; Pourhoseingholi MA; Shokouhi S; Darazam IA
    Trials; 2020 Jun; 21(1):473. PubMed ID: 32493468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective Study.
    Huang YQ; Tang SQ; Xu XL; Zeng YM; He XQ; Li Y; Harypursat V; Lu YQ; Wan Y; Zhang L; Sun QZ; Sun NN; Wang GX; Yang ZP; Chen YK
    Front Pharmacol; 2020; 11():1071. PubMed ID: 32765274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19: A structured summary of a study protocol for a randomized controlled l trial.
    Alavi Darazam I; Hatami F; Rabiei MM; Pourhoseingholi MA; Moradi O; Shokouhi S; Hajesmaeili MR; Shabani M; Irvani SSN
    Trials; 2020 Oct; 21(1):880. PubMed ID: 33106183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative therapeutic efficacy of interferon alfa-2b and combination lopinavir/ritonavir plus interferon alfa-2b against SARS-CoV-2.
    Liu J; Du C; Pu L; Xiang P; Xiong H; Xie W; Chen Z; Li A
    BMC Infect Dis; 2021 Aug; 21(1):885. PubMed ID: 34461841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic and health-related quality-of-life (HRQoL) comparison of lopinavir/ritonavir (LPV/r) and atazanavir plus ritonavir (ATV+RTV) based regimens for antiretroviral therapy (ART)-naïve and -experienced United Kingdom patients in 2011.
    Simpson KN; Baran RW; Collomb D; Beck EJ; Van de Steen O; Dietz B
    J Med Econ; 2012; 15(4):796-806. PubMed ID: 22563716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus.
    Martinez MA
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32152082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of (interferon beta-1b, lopinavir/ritonavir and ribavirin) versus favipiravir in hospitalized patients with non-critical COVID-19: A cohort study.
    A Malhani A; A Enani M; Saheb Sharif-Askari F; R Alghareeb M; T Bin-Brikan R; A AlShahrani S; Halwani R; Tleyjeh IM
    PLoS One; 2021; 16(6):e0252984. PubMed ID: 34111191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia.
    Solaymani-Dodaran M; Ghanei M; Bagheri M; Qazvini A; Vahedi E; Hassan Saadat S; Amin Setarehdan S; Ansarifar A; Biganeh H; Mohazzab A; Khalili D; Hosein Ghazale A; Reza Heidari M; Taheri A; Khoramdad M; Mahdi Asadi M; Nazemieh M; Varshochi M; Abbasian S; Bakhtiari A; Mosaed R; Hosseini-Shokouh SJ; Shahrokhi M; Yassin Z; Ali Zohal M; Qaraati M; Rastgoo N; Sami R; Javad Eslami M; Asghari A; Namazi M; Ziaie S; Jafari-Moghaddam R; Kalantari S; Memarian M; Khodadadi J; Hossein Afshari M; Momen-Heravi M; Behzadseresht N; Reza Mobayen A; Mozafari A; Movasaghi F; Haddadzadeh Shoushtari M; Moazen J
    Int Immunopharmacol; 2021 Jun; 95():107522. PubMed ID: 33735712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and safety of Ivermectin in patients with mild and moderate COVID-19: A structured summary of a study protocol for a randomized controlled trial.
    Hosseini FS; Malektojari A; Ghazizadeh S; Hassaniazad M; Davoodian P; Dadvand H; Nikpoor AR; Nikoofal-Sahlabadi S; Kahoori S; Sepandi M; Hassanipour S; Fathalipour M
    Trials; 2021 Jan; 22(1):4. PubMed ID: 33397429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lopinavir/ritonavir versus darunavir plus ritonavir for HIV infection: a cost-effectiveness analysis for the United States.
    Simpson KN; Pei PP; Möller J; Baran RW; Dietz B; Woodward W; Migliaccio-Walle K; Caro JJ
    Pharmacoeconomics; 2013 May; 31(5):427-44. PubMed ID: 23620210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.
    Johnson M; Grinsztejn B; Rodriguez C; Coco J; DeJesus E; Lazzarin A; Lichtenstein K; Rightmire A; Sankoh S; Wilber R
    AIDS; 2005 Apr; 19(7):685-94. PubMed ID: 15821394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.
    Hung IF; Lung KC; Tso EY; Liu R; Chung TW; Chu MY; Ng YY; Lo J; Chan J; Tam AR; Shum HP; Chan V; Wu AK; Sin KM; Leung WS; Law WL; Lung DC; Sin S; Yeung P; Yip CC; Zhang RR; Fung AY; Yan EY; Leung KH; Ip JD; Chu AW; Chan WM; Ng AC; Lee R; Fung K; Yeung A; Wu TC; Chan JW; Yan WW; Chan WM; Chan JF; Lie AK; Tsang OT; Cheng VC; Que TL; Lau CS; Chan KH; To KK; Yuen KY
    Lancet; 2020 May; 395(10238):1695-1704. PubMed ID: 32401715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors associated with prolonged viral shedding and impact of lopinavir/ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection.
    Yan D; Liu XY; Zhu YN; Huang L; Dan BT; Zhang GJ; Gao YH
    Eur Respir J; 2020 Jul; 56(1):. PubMed ID: 32430428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19.
    Ader F; Peiffer-Smadja N; Poissy J; Bouscambert-Duchamp M; Belhadi D; Diallo A; Delmas C; Saillard J; Dechanet A; Mercier N; Dupont A; Alfaiate T; Lescure FX; Raffi F; Goehringer F; Kimmoun A; Jaureguiberry S; Reignier J; Nseir S; Danion F; Clere-Jehl R; Bouiller K; Navellou JC; Tolsma V; Cabié A; Dubost C; Courjon J; Leroy S; Mootien J; Gaci R; Mourvillier B; Faure E; Pourcher V; Gallien S; Launay O; Lacombe K; Lanoix JP; Makinson A; Martin-Blondel G; Bouadma L; Botelho-Nevers E; Gagneux-Brunon A; Epaulard O; Piroth L; Wallet F; Richard JC; Reuter J; Staub T; Lina B; Noret M; Andrejak C; Lê MP; Peytavin G; Hites M; Costagliola D; Yazdanpanah Y; Burdet C; Mentré F;
    Clin Microbiol Infect; 2021 Dec; 27(12):1826-1837. PubMed ID: 34048876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.